Metabolic Syndrome in Childhood Cancer Survivors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03773718|
Recruitment Status : Recruiting
First Posted : December 12, 2018
Last Update Posted : December 20, 2018
The research is devoted to studying the features of the metabolic syndrome in cancer survivors in childhood is supposed to answer the following questions:
- How can metabolic syndrome be diagnosed in the Russian population of survivors of acute lymphoblastic leukemia and non-Hodgkin's lymphomas?
- What are the features of the clinical symptoms of metabolic syndrome in this category of patients?
- Which genetic mutations are found in cancer survivors of patients with metabolic syndrome; Which of these mutations can be considered as protective or vice versa predisposing to the development of metabolic syndromes? Is the metabolic syndrome associated with an increased frequency of toxic complications of therapy during the intensive stages?
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Study of the Pathogenic Mechanisms of Metabolic Syndrome at the Background of Genetically Determined Insulin Resistance in Childhood Cancer Survivors|
|Actual Study Start Date :||November 20, 2018|
|Estimated Primary Completion Date :||September 20, 2021|
|Estimated Study Completion Date :||December 20, 2022|
- The frequency of metabolic syndrome [ Time Frame: 12 months ]The frequency of diagnosed metabolic syndrome in the cohort of children and adolescents with leukemia and lymphomas
- Genetic risk [ Time Frame: 12 months ]The detection of NSP associated with metabolic syndrome in children and adolescents after childhood cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773718
|Contact: Elena V. Zhukovskaya, MDemail@example.com|
|Contact: Tatiana V. Nasedkina, PhDfirstname.lastname@example.org|
|Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology||Recruiting|
|Moscow, Russian Federation, 117997|
|Contact: Alexander F Karelin, PhD +74952876570 email@example.com|
|Sub-Investigator: Anna E Gavrilova, PhD|
|Study Chair:||Melissa M. Hudson, MD||St. Jude Children's Research Hospital Memphis, TN 38105|